このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Exploring the Interplay Between Maternal Stress, Human Milk, and Epigenetic Changes in Preterm Infant's Neurodevelopment (EMBRACE)

2026年11月11日 更新者:Camilla Fontana、Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico

Preterm birth represents a major challenge in pediatric healthcare, as preterm infants are at increased risk of neonatal complications and long-term neurodevelopmental impairments. Several factors may contribute to these outcomes, including gestational age at birth, postnatal comorbidities, and the neonatal intensive care unit (NICU) environment. Furthermore, preterm birth and prolonged hospitalization may negatively affect maternal psychological well-being, increasing the risk of stress, anxiety, and depression. These conditions may influence maternal sensitivity and responsiveness, mother-infant interactions, and infant neurodevelopment.

Emerging evidence suggests that maternal mental health may affect infant neurodevelopment through both direct biological mechanisms, such as epigenetic regulation, and indirect pathways, including changes in breast milk composition. Cortisol, a stress-related hormone present in breast milk and saliva, may play a role in stress regulation and neurobehavioral development. In particular, the methylation of Long Interspersed Nuclear Element-1 (LINE-1 or L1), a mobile genetic element involved in genomic regulation, may be influenced by environmental factors and early maternal care. Preliminary findings indicate that preterm infants exhibit lower L1 promoter methylation levels at birth than term infants, while early maternal care may modulate these levels and support neurobehavioral development.

The EMBRACE study aims primarily to investigate the relationship between biological maternal stress, measured through salivary cortisol levels, and L1 promoter methylation in blood samples collected from preterm infants from birth to 12 months of corrected age. Secondary objectives include examining this relationship in buccal swab samples, assessing associations between maternal perceived stress, anxiety, and depression and infant L1 methylation, and investigating the relationship between maternal psychological and biological stress indicators and infant neurodevelopmental outcomes. The study will also explore associations between perceived maternal stress and cortisol concentrations in breast milk and saliva, as well as longitudinal changes in L1 methylation.

This is a non-pharmacological, observational cohort study conducted at the Neonatology and Neonatal Intensive Care Unit of the Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico in Milan, Italy. Participants will include preterm infants born between 24+0 and 30+6 weeks of gestational age and their mothers. Assessments will be conducted at five time points: birth, transition to intermediate care or 34 weeks of postmenstrual age, hospital discharge, 6 months, and 12 months of corrected age. Maternal assessments will include standardized questionnaires evaluating stress, anxiety, and depression, as well as cortisol measurements in saliva and breast milk. Infant assessments will include L1 methylation analyses in blood and buccal samples and standardized neurodevelopmental evaluations as part of routine clinical follow-up. No additional invasive procedures will be performed, as blood samples will be collected during routine clinical care.

The study is expected to improve understanding of the relationships between maternal stress, anxiety, depression, epigenetic regulation, and neurodevelopment in preterm infants. It will also investigate the potential role of breast milk cortisol in these associations. Ultimately, the findings may contribute to the development of early interventions aimed at improving neurodevelopmental outcomes in preterm infants and supporting maternal psychological well-being.

調査の概要

研究の種類

観察的

入学 (推定)

96

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究場所

    • Lombardy
      • Milan、Lombardy、イタリア、20122
        • 募集
        • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
        • コンタクト:
        • 副調査官:
          • Chiara Bonfanti
        • 副調査官:
          • Agnese De Carli
        • 副調査官:
          • Monica Fumagalli
        • 副調査官:
          • Mary Giorgia Gaccione

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

5ヶ月~6ヶ月 (子)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

サンプリング方法

非確率サンプル

調査対象母集団

All preterm infants born at the SC Neonatologia e Terapia Intensiva Neonatale - Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Milano and their mothers.

説明

Inclusion Criteria:

  • Preterm infants born between 24+0 and 30+6 weeks of gestational age (GA);
  • Mothers aged ≥ 18 years with adequate understanding of the Italian language;
  • Signed informed consent from parents.

Exclusion Criteria:

  • Parents decline participation;
  • Infants with major congenital anomalies, malformations, or genetic syndromes;
  • Mothers with obvious psychiatric conditions, cognitive deficits, or active substance abuse at the time of delivery.
  • Infants birth samples not available (both buccal swab and blood)

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 観測モデル:COHORT
  • 時間の展望:PROSPECTIVE

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Epigenetic changes on LINE1 (blood samples)
時間枠:up to 48 weeks post menstrual age

epigenetic analysis is performed on cord blood samples collected at birth, at transition to intermediate care and at hospital discharge on peripheral blood samples

up to 48 weeks post menstrual age
Maternal salivary cortisol
時間枠:up to 12 months corrected age of the infant

Collected at birth, transition to intermediate care, discharge

up to 12 months corrected age of the infant

二次結果の測定

結果測定
メジャーの説明
時間枠
Human milk cortisol concentrations
時間枠:up to 6 months corrected age of the infant

Collected at birth, transition to intermediate care, discharge

up to 6 months corrected age of the infant
Buccal swab
時間枠:up to 12 months corrected age

Collected at birth, 34 weeks GA, discharge, 6 and 12 months corrected age

up to 12 months corrected age
Neurological outcome
時間枠:up to 44 weeks post menstrual age

Hammersmith neonatal neurological examination performed at NICU discharge

up to 44 weeks post menstrual age
Neonatal Visual Assessment
時間枠:up to 44 weeks post menstrual age

Neonatal visual function in assessed at discharge using the Visual Assessment battery developed by Ricci et al. The assessment has 9 items and each one is scored as normal or abnormal according to the description given by the authors.

up to 44 weeks post menstrual age
Neonatal behavior
時間枠:up to 44 weeks post menstrual age

Neonatal behavior is assessed using the Neonatal Behavior Assessment Scale, and in particular the areas of state organization, state regulation, and the autonomic system. Each item will be scored according to the description given by the author of the assessment

up to 44 weeks post menstrual age
Neurodevelopmental outcome
時間枠:from 6 to 12 months corrected age

Bayley scales to assess neurodevelopment at 6 and 12 months corrected age. The normal range for the composite score is 100 +/- 15 points. Higher scores mean better outcomes.

from 6 to 12 months corrected age
Maternal depression
時間枠:up to 12 months corrected age of the infant

Assessed with the Edinburgh Postnatal depression scale. Responses are scored 0 to 3. A score above 8 is considered pathological in the post partum period. It will be administered at birth, at transition to intermediate care, at NICu discharge at 6 and 12 months corrected age.

up to 12 months corrected age of the infant
Maternal stress in the NICU
時間枠:up to 12 months corrected age of the infant

Assessed with the Parental Stressor Scale: Neonatal Intensive Care Unit (PSS:NICU). It is composed of 35 items that are scored on a 5-point Likert scale ranging from 1 (not stressful at all) to 5 (extremely stressfull). It will be administered at birth, at transition to intermediate care and at NICu discharge.

up to 12 months corrected age of the infant
Maternal bonding
時間枠:up to 12 months corrected age of the infant

Assessed with the Postpartum Bonding Questionnaire (PBQ) administered at NICU discharge, 6 and 12 months corrected age. A score above 26 is considered pathological.

up to 12 months corrected age of the infant
Maternal anxiety and depression
時間枠:up to 12 months corrected age of the infant

Assessed with the hospital anxiety and depression scale (HAD-S). It will be administered at birth, at transition to intermediate care, at NICu discharge at 6 and 12 months corrected age. A score from 0 to 7 is normal, 8-10 borderline and 11-21 score in the clinical range.

up to 12 months corrected age of the infant
Parenting stress
時間枠:up to 12 months corrected age of the infant

Assessed with the Parenting Stress Index Scale. Administered at 6 and 12 months corrected age. It is composed of 36 items that are scored on a 5-point Likert scale ranging from 1 (not stressful at all) to 5 (extremely stressful)

up to 12 months corrected age of the infant

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2026年8月25日

一次修了 (推定)

2027年6月1日

研究の完了 (推定)

2028年12月1日

試験登録日

最初に提出

2026年11月5日

QC基準を満たした最初の提出物

2026年11月11日

最初の投稿 (実際)

2026年11月17日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月17日

QC基準を満たした最後の更新が送信されました

2026年11月11日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • EMBRACE

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

未定

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する